Skip to main content
MedPathMedPath Home
Clinical Trials/IRCT20161206031256N2
IRCT20161206031256N2
Completed
Phase 2

Evaluation of the Effectiveness of Intralymphatic Allergen Immunotherapy in patients with Allergic Rhinitis

Vice chancellor for research, Mashhad University of Medical Sciences0 sites15 target enrollmentTBD
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
Not specified
Sponsor
Vice chancellor for research, Mashhad University of Medical Sciences
Enrollment
15
Status
Completed
Last Updated
8 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
8 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
Vice chancellor for research, Mashhad University of Medical Sciences

Eligibility Criteria

Inclusion Criteria

  • •Patients with Seasonal or Perennial Allergic Rhinitis
  • •Aggravated symptoms from mid Summer till mid Autumn for at least two years
  • •Age :15\-65 years
  • •Positive Skin Prick Test response to Salsola Kali
  • •Symptoms remain troublesome despite treatment
  • •The ability to comply with study procedures

Exclusion Criteria

  • •Past history of Autoimmune Diseases
  • •Ongoing Systemic Immunosuppressive treatment.
  • •The presence of Pregnancy
  • •The presence of Immunodeficiency
  • •The presence of Allergic Asthma
  • •The presence of Heart Diseases
  • •Ongoing Beta Blocker or ACE inhibitors drug usage
  • •The presence of Malignancy
  • •The presence of any chronic diseases
  • •Current symptoms of Upper Respiratory Tract Infection

Outcomes

Primary Outcomes

Not specified

Similar Trials

Terminated
Not Applicable
The efficacy and adverse effect of intralymphatic immunotherapy (ILIT) for allergic diseasesDiseases of th respiratory system
KCT0001534Gachon University Gil Medical Center144
Recruiting
Not Applicable
Intralymphatic immunotherapy with Tyrosine S®, allergen extract for immunotherapyDiseases of th respiratory system
KCT0001777Gachon University40
Recruiting
Phase 2
Evaluation of Lymphatic flow using indocyanine green fluorescence imagingColorectal adenocarcinoma
JPRN-jRCTs061210023Kondo Akihiro100
Active, not recruiting
Phase 1
Effect of intralymphatic immunotherapyAllergic rhinitisMedDRA version: 21.1Level: PTClassification code 10039085Term: Rhinitis allergicSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersMedDRA version: 20.0Level: PTClassification code 10010744Term: Conjunctivitis allergicSystem Organ Class: 10015919 - Eye disordersMedDRA version: 20.0Level: PTClassification code 10003553Term: AsthmaSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersTherapeutic area: Body processes [G] - Immune system processes [G12]
EUCTR2020-001060-28-DKAarhus Universitet528
Completed
Not Applicable
INTACT-Lymph_Interventional approach to lymphatic leakageT81.9Unspecified complication of procedure
DRKS00015299Klinikum der Universität München, Campus Großhadern100